A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI.
Daniël M F ClaassensGerrit J A VosThomas O BergmeijerRenicus S HermanidesArnoud W J van 't HofPim van der HarstEmanuele BarbatoCarmine MoriscoRichard M Tjon Joe GinFolkert W AsselbergsArend MosterdJean-Paul R HerrmanWillem J M DewildePaul W A JanssenJohannes C KelderMaarten J PostmaAnthonius de BoerCornelis BoersmaVera H M DeneerJurriën M Ten BergPublished in: The New England journal of medicine (2019)
In patients undergoing primary PCI, a CYP2C19 genotype-guided strategy for selection of oral P2Y12 inhibitor therapy was noninferior to standard treatment with ticagrelor or prasugrel at 12 months with respect to thrombotic events and resulted in a lower incidence of bleeding. (Funded by the Netherlands Organization for Health Research and Development; POPular Genetics ClinicalTrials.gov number, NCT01761786; Netherlands Trial Register number, NL2872.).
Keyphrases
- percutaneous coronary intervention
- acute coronary syndrome
- st segment elevation myocardial infarction
- antiplatelet therapy
- st elevation myocardial infarction
- patients undergoing
- coronary artery disease
- acute myocardial infarction
- atrial fibrillation
- coronary artery bypass grafting
- risk factors
- clinical trial
- phase iii
- combination therapy
- coronary artery bypass
- mesenchymal stem cells
- left ventricular
- cell therapy